ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACHV vs QDEL // GROSS PROFIT MARGIN

Achieve Life Sciences Inc. (NASDAQ) VS. QuidelOrtho Corporation (NASDAQ) • 15-METRIC TALLY: ACHV 1 — QDEL 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHV VS. QDEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACHV QDEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.69% -8.80% +2.11 ACHV /fcf-yield <GO>
Operating Margin — -33.70% — TIE /operating-margins <GO>
Net Profit Margin — -41.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — -1.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 QDEL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.4 51.1 -4.66 QDEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $739.9M $943.6M -$203.7M QDEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACHV REV QDEL REV ACHV GROSS % QDEL GROSS % ACHV FCF QDEL FCF
FY 2025 $0 $2.73B — — -$49.5M -$83.0M
FY 2024 $0 $2.78B — — -$29.8M -$112.1M
FY 2023 $0 $3.00B — — -$24.5M $280.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHV // BETA —
QDEL // BETA —